Nuo Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 30, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 30, 2026
AURXStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
Nuo Therapeutics, Inc.
Consolidated Statements of Operations
| Year ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Revenue | ||
| Product sales | $3,088,509 | $1,365,173 |
| License revenue | 225,000 | - |
| Total revenue | 3,313,509 | 1,365,173 |
| Costs of sales | 1,095,553 | 302,842 |
| Gross profit | 2,217,956 | 1,062,331 |
| Operating expenses | ||
| Selling, general and administrative | 4,734,605 | 3,520,166 |
| Total operating expenses | 4,734,605 | 3,520,166 |
| Loss from operations | (2,516,649) | (2,457,835) |
| Other income (expense) | ||
| Interest income (expense), net | (804) | 105 |
| Gain on settlement of legacy accounts payable obligations | - | 133,623 |
| Other income | 5,237 | 402 |
| Loss before benefit for income taxes | (2,512,216) | (2,323,705) |
| Net loss | $(2,512,216) | $(2,323,705) |
| Net loss per share – basic and diluted | $(0.05) | $(0.05) |
| Weighted average shares outstanding – basic and diluted | 47,312,727 | 45,424,437 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.